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Sununary Menogaril is an anthracycline presently in Phase II clinical trials. Menogaril-resistant mouse
leukaemia P388 cells were developed in vitro by 4 months of exposure to step-wise increasing concentrations of
menogaril after which resistant cells (P388/MEN) were cloned in 320 ng ml- ' menogaril. P388/MEN cells were
40-fold more resistant to menogaril in vitro compared to P388/0 and were also resistant in vivo. Resistance to
menogaril was stable for at least 2 months in the absence of the drug. The results indicate that P388/MEN,
although resistant to an anthracycline, did not dispay the typical multidrug resistant phenotype. It was not
cross-resistant to several structurally unrelated drugs such as actinomycin D, cisplatin, or vinblastine, but it
was cross-resistant to the anthracycline, adriamycin. Uptake and efflux of menogaril was similar in sensitive
and resistant cell lines. Also, resistance was not reversed by verapamil. No major karyotypic difference was
noted between P388/0 and P388/MEN. There was no significant amplification or overexpression of the mdr
gene in P388/MEN compared to P388/0. In contrast to P388/MEN, P388 cells resistant to adriamycin
displayed the typical multidrug resistant phenotype. Glutathione content of P388/MEN cells was similar to
that of P388/0 and depletion of glutathione did not potentiate menogaril cytotoxicity. Therefore, we conclude
that glutathione is not likely to be involved in menogaril resistance to P388/MEN cells.
Menogaril, also known as 7-OMEN, menogarol, or 7-(R)-0-
methylnogarol, is an anthracycline in Phase II clinical trials
(Stemnberg et al., 1986). It entered clinical trial by virtue of its
broad spectrum of antitumour activity against transplantable
animal tumours (Neil et al., 1979) even when given orally
(McGovren, 1980), its activity against human tumour cells in
the cloning assay (Weiss et al., 1983), a lower potential for
cardiotoxicity (McGovren et al., 1979) and a site of action
different from that of adriamycin (Bhuyan et al., 1980; Li et
al., 1979). The biochemical activity of adriamycin and
menogaril are markedly different in the following respects: at
cytotoxic doses, adriamycin inhibited RNA synthesis more
than DNA synthesis in L1210 cells in culture, whereas
menogaril caused very little inhibition of RNA or DNA
synthesis at cytotoxic doses (Li et al., 1979); adriamycin
interacted strongly with DNA, whereas menogaril interacts
weakly (Li et al., 1979); S phase cells were most sensitive to
adriamycin, whereas G, cells were most sensitive to
menogaril (Bhuyan et al., 1980). These results collectively
suggest that menogaril acts through some mechanism other
than the intercalative DNA binding proposed for adriamycin.
The development of a population of cells within a tumour
resistant to antineoplastic agents is of obvious clinical
significance. In many cases, as was documented with
adriamycin, development of resistance to one drug was
associated with cross-resistance to several structurally
unrelated drugs (Kartner et al., 1983; Schabel et al., 1983;
Johnson et al., 1978; Kaye and Merry, 1985). This multidrug
resistant phenotype was shown to include: cross-resistance to
structurally unrelated agents (Kartner et al., 1983); reversal
of resistance with verapamil (Klohs et al., 1986); decreased
intracellular drug concentration by decreased drug uptake, or
increased efflux (Ling & Thompson, 1974); and amplification
or overexpression of one or more mdr associated genes (Rior-
dan et al., 1985). Because menogaril is an anthracycline
similar in structure to adriamycin, it is of clinical significance
to find out if menogaril-resistant cells are also pleiotropically
resistant. Our results show that the phenotypes of menogaril-
and adriamycin-resistant P388 cells are different. Parts of this
paper were previously presented as an abstract (Badiner &
Bhuyan, 1986a; Moy et al., 1986).
Materials and methods
Methods
Cell culture conditions and characterisations P388 cells were
obtained from NCI-Frederick (Frederick, MD 21707).
Adriamycin-resistant P388 (P388/Adr) were obtained from
Southern Research Institute (Birmingham AL 35255). Cells
were grown in vitro in RPMI 1640 with 5% FCS in a 5%
CO2 humidified incubator and maintained in exponential
growth by subculturing prior to 5 x 105cells/ml. Chinese
hamster CHrC5 and AuxB, cell lines were obtained from I.
Abraham (The Upjohn Company, Kalamazoo, MI 49001)
and maintained as previously described (Bech-Hansen et al.,
1975). Cells were suspended in growth medium with 7%
DMSO and then frozen in liquid nitrogen. All cell stocks
were free of Mycoplasma contamination. Stocks removed
from liquid nitrogen were passaged in vitro for 2 weeks
before experimental use. Cells were karyotyped and isozyme
patterns were determined by Dr. Ward Peterson (Children's
Hospital, Detroit, MI) using standard techniques (Ottenbreit
et al., 1983; Peterson et al., 1979).
Resistance development protocol was as follows. P388 cells
were maintained at I0O cells ml-' x 500ml in a 1 I Bellco
roller bottle (Bellco, Vineland, NJ 08360) at 1.2 r.p.m. with
an initial concentration of 1.6 ngml' menogaril. When cells
grew to 106 cells ml-', the culture was diluted to
105 cells ml-' with fresh medium containing drug. When cells
could grow at a given concentration for 2 to 3 passages, the
dose of drug was then doubled. This procedure was repeated
until cells could grow at 0.32fig ml-' menogaril. The percent
of viable cells was determined by mixing cells in growth
medium with an equal volume of 0.4% trypan blue.
For in vivo studies, P388 cells were passaged in CDF,
female mice by weekly i.p. injection of 106 cells. The mice
were kept in a barrier facility and MAP testing performed by
M.A. Bioproducts (Walkersville, MD 21793) showed that the
mice colonies were free from viral contamination. For in vivo
experiments, 6 BDF, male mice (20 g) per cage were used for
each dose ofdrug. The mice were fed and watered ad lib. and
were injected on day 0 with 106 cells i.p. (in 0.2 ml Dulbec-
co's PBS). Drug injections (0.1 ml) were given i.p. on days 1,
5 and 9. Dead mice were counted and removed daily, and all
experiments were terminated on day 60. Survivors at day 60
were termed cures.
Cell survival after drug exposure was determined by clon-
ing in soft agar medium, as described in detail previously
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(Badiner et al., 1987b). Briefly, after drug exposure, the cells
were pelleted by low-speed centrifugation and washed twice
with warm medium. Cells were then serially diluted in fresh
growth medium and an aliquot planted in a soft-agar cloning
medium to give 20 to 100 colonies per tube after 8-10 days
incubation in a 8% C02-humidified incubator. RPMI 1640
supplemented with 20% fetal calf serum and penicillin
(0.1 mgml1), streptomycin (0.05 mgml-') and containing
0.1% Noble agar (Difco) constituted the cloning medium.
Colonies were counted visually. The cloning efficiency of the
untreated cells acted as the control and was normalised to
100% survival. Cloning efficiency of the drug-treated cells
was expressed as a percentage of control survival. For sur-
vival determination 4 tubes per dose were used.
Growth inhibition was determined by incubating 2 x 104
cells ml-' from an exponentially grown culture with drug for
72 h. Details are published elsewhere (Badiner et al., 1987b).
Cell numbers were determined after 72 h by counting in a
ZBI Coulter counter (Coulter Electronics, Hialeah, FL).
Growth of the treated cultures was expressed as a % of
growth of the untreated control by the equation shown
below:
% of control growth = 100 x
Final cell number/treated - Initial cell number planted
Final cell number/control - Initial cell number planted
The curve generated by plotting growth inhibition vs dose
was used to calculate the 50% (ID_o) and the 90% (ID90)
growth inhibitory dose. Samples were run in duplicate and
data points shown are sample means. Variation between
experiments was generally less than 10% for a given mean
value. All work with menogaril was performed in minimal
light, and the cells were incubated with the drug in light-tight
chambers. Drug solutions were prepared as follows. Meno-
garil and adriamycin were dissolved in 0.01 M glucuronic
acid; actinomycin D was dissolved in 95% ethanol; vinblas-
tine and cisplatin were dissolved in water. All solutions
(except cisplatin, which was prepared fresh) were stored
frozen at 1 mgml-' protected from light. Verapamil (Isoptin)
was prepared fresh.
Menogaril uptake and efflux determination Cellular drug
uptake was measured during 2 h incubation with menogaril,
following which the cells were centrifuged, washed, and
resuspended in growth medium. Efflux ofdrug was measured
during the next 3 h incubation at 37'C. For measuring intra-
cellular drug by HPLC, cell samples were centrifuged, the
medium was aspirated and tubes were inverted and drained
on filter paper. Cell pellets were dispersed in 200Mil of 0.01 M
glucuronic acid and stored frozen until assayed. The
measurement of menogaril by HPLC has been described
previously (McGovren et al., 1984). The internal standard,
7-con-O-ethylnogaril, was dissolved in 0.01 M glucuronic acid
and 100lI of 25 igml-' internal standard was added to
tubes containing 200Ml of 0.01 M glucuronic acid blanks, or
to dispersed cell pellets in 200Mil of glucuronic acid. The cell
samples were deproteinised by adding 0.01 M glucuronic acid,
and 800l of methanol/acetonitrile (50/50) extraction sol-
vent. The tubes were vortexed, centrifuged at 27,000g for
15 min and 300Ml of the supernatant injected into a Waters
Radial-Pak CB column (Waters Assoc., Milford, MA). The
mobile phase consisted of buffer and acetonitrile mixture
(60/40). The buffer solution consisted of 2.88 ,I methane
sulfonic acid, 2.0% glacial acetic acid (v/v), and 0.041%
triethylamine (v/v). The flow rate was 1.5mlmin-' and the
eluate was monitored at 400 nm excitation and 540 am emis-
sion. The retention time for menogaril was approximately
7min. The peak heights of known standards were plotted against concentration to generate a standard curve. Peak
heights of the unknown sample were compared to the stan-
dard curve to measure the amount of menogaril.
DNA/RNA hybridisations Cellular DNA was isolated ac-
cording to previously published protocol (Maniatis et 41.,
1982) and suspended in 10 mM Tris, pH 7.4 and 1 mM
EDTA. DNA (10jig) was digested with BamHl, electro-
phoresed on a 0.8% agarose gel and then transferred to a
GeneScreenPlus nylon membrane by the method of Southern
as described in Maniatis et al. (1982). The filter was hy-
bridised according to the manufacturer's (New England
Nuclear) specifications. The filter was washed to a final
stringency of 2X SSC and 1% SDS at 65° for 30 min. The
probe used was pDR 1.6 (obtained from P. Gros, McGill
University, Montreal, Quebec, Canada) which is a pUC19
plasmid containing a 1.6kpb BgI2 fragment of a hamster
mdr gene (Gros et al., 1986). The probe was labelled with 32P
by nick translation. Washed membranes were exposed for
4-16 h at - 70°C to Kodak X-Omat AR film with an inten-
sifying screen.
Total cellular RNA was isolated as previously described
(Chirgwin et al., 1979). RNA (10Mg) was dissolved in buffer
(3.42 MlI glyoxal, 30ML 1 M sodium phosphate - pH 6.8, 1.5 ml
DMSO, 30Ml 10% SDS and 100Mil water) and electro-
phoresed in a 1.5% agarose gel with recirculated 10 mM
sodium phosphate running buffer. Fractionated RNA was
transferred to a Nytran membrane by electroblotting over-
night at 20 volts and 4'C. The blots were washed in 6 x SSC
and then crosslinked with u.v. The 1.6 kbp insert from the
plasmid pDR 1.6 (Gros et al., 1986) was isolated and labelled
with 32P by random priming (Feinberg & Vogelstein, 1984) to
a specific activity of 1.8 x 109c.p.m. Mg-'. Membranes were
hybridised overnight at 65°C with 1.5 x 108 c.p.m., washed
twice with 1 mm sodium EDTA, 40mM sodium phosphate,
5% SDS and 0.5% BSA, then washed 4 times with 1% SDS.
All washes were at 65°C for 10 min. Blots were then rinsed in
0.1 x SSC at room temperature and exposed to XAR X-ray
film for several hours. RNA standard was a random-primed
32P-labelled cellular RNA from S49 mouse cells which was
applied at 5 x 103c.p.m. relative to 28S and 18S RNA.
Cellular glutathione (GSH) determination GSH levels in
cells was determined by the method of Nakashima et al.
(1986). Briefly, cells suspended in 20 mM EDTA were
homogenised in an ice bath. Cell homogenate was treated
with 30% HPO3 at a level of 20% of the homogenate volume
and then centrifuged. The supernatant (0.2 ml) was mixed
with 0.05 ml of 2 M KOH, 2.25 ml of a 0.1 M borate-
carbonate buffer (pH 8.5), and 2.5 ml of the fluorogenic rea-
gent (8 Mm) in CH3CN. The fluorogenic reagent was N-{p-[2-
(6&dimethylamino)-benzofuranyl]-phenyl} maleimide, and was
used as acetonitrile solution. The mixture was heated at 600C
for 30 min, then cooled to room temperature. The relative
fluorescence intensity was measured at 457 nm with excita-
tion at 355 nm. The fluorescence intensity of the samples
were compared to that of GSH standard curve. When a
known amount of GSH was added to a cell homogenate, it
was recovered with 95-105% efficiency.
Materials
Tissue culture supplies were obtained from the following
sources: RPMI 1640, K.C. Biologicals, Lenexa, KS 66215;
FCS, Hyclone, Logan, UT 84321; PBS, Gibco, Grand Island,
NY 14072. Trypan Blue, SDS, dextran sulfate, salmon sperm
DNA, EDTA, sodium phosphate, BSA, buthionine sulfoxi-
mine, and glucuronic acid were purchased from Sigma, St.
Louis, M063178. Drugs were obtained as follows: meno-
garil, The Upjohn Company, Kalamazoo MI49001;
adriamycin, National Cancer Institute, National Institute of
Health, Bethesda, M)20892; actinomycin D, Calbiochem-
Behring Corp, LaJoUa, CA92037; verapamil, Knoll Pharma-
ceutical Company, Whippany, NJ 07981; Velban0, Lilly,
Indianapolis, IN46285; and cisplatin, Bristol Laboratories,
Syracuse, NY 13201. Agarose was obtained from BRL,
Gaithersburg, MD20877; GeneScreenPlus nylon membrane
from New England Nuclear, Boston, MA 02118; Nytran
membrane from Schleicher-Schuell, Keene, NH 03431.
BamHl was obtained from Biolabs, Beverley, MA 01915.380 G.J. BADINER et al.
Results
Development of menogaril resistant P388 cells The 50%
growth inhibitory dose of P388/0 cells to menogaril is
16 ng ml-'. However, cells did not grow when they were
maintained continuously in concentrations higher than
1.6 ng ml-'. P388 cells initially exposed to 0.5 to 1.6 ng ml'
of menogaril had an 18-day lag before slow but continuous
cell growth occurred. When the drug-treated cultures had
generation times similar to the untreated control cells for 2 to
3 passages, the menogaril concentration was doubled. As the
culture adapted to continuous exposure to menogaril, the
time between stepwise increase in drug dose decreased. This
protocol was followed for 4 months until the cells grew well
in 320 ng ml-' menogaril. Drug concentrations greater than
320 ng ml-' decreased the growth rate and cells failed to
survive.
Cells growing in 0.32 pg ml-' menogaril were cloned in
soft agar medium and 20 clones were isolated. The clones
had similar doubling times (20-27 h) and sensitivities in the
growth inhibition assay (ID,o values range 0.5-0.7 Lsgml-').
However, significant differences were seen in their cloning
efficiency in soft agar (range from 25 to 66%) and one clone
failed to grow. The clones also differed in their survival after
drug exposure, e.g., at 0.32 jig ml-' menogaril, the survival
ranged from 30-100%. Clone 13 was selected for further
study because of its high cloning efficiency (66%) and high
level of drug resistance and was designated P388/MEN.
Figure 1 shows cell survival after 2 h of exposure to the drug.
P388/MEN was 25-fold resistant to menogaril at both the
LD,0 (= 2.2 jig ml-') and LD90 values as compared to P388/
0. P388/MEN (ID50 = 0.64fig ml-') was 40-fold resistant to
menogaril in the growth inhibition assay compared to P388/
0. Resistance was stable for at least 2 months in the absence
of menogaril.
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Figure 1 Cell survival of P388/0 and P388/MEN after 2 h
exposure to menogaril. Data points are sample means, different
symbols represent separate experiments. Open symbols represent
P388/MEN and closed symbols represent P388/0.
Ten P388/0 clones were also examined and no significant
differences were seen among these clones in growth rate,
clonogenicity in soft agar and ID_o or LD^o values after
exposure to menogaril (data not shown).
Cell morphology andelectron microscope studies The P388/0
and P388/Adr cell lines grew as single cell suspension with
relatively few cell aggregates. All of the menogaril-resistant
clones formed dense cellular aggregates which were easily
dispersed with a pipette. Cell surface morphology, as demon-
strated by scanning electron micropscopy, did not show any
significant differences between the sensitive and resistant
P388 cell lines.
Isozyme and karyotype analysis of P388 and P388/MEN cells
show minor differences Isozyme analysis of G6PD, LDH,
MDH and NP present in cell extracts from P388/0 and
P388/MEN cell lines showed these to be of mouse origin.
Karyotypes of P388/0 and P388/MEN were determined and
the results are described below. P388/0 had chromosomes
typical of mouse origin with 85 of 100 metaphases having
36-40 chromosomes (2N = 40) and 15 metaphases with
79 chromosomes. One marker chromosome (M1) present
in all P388/0 karyotypes was a #2 chromosome with an
insertion in the B region. P388/MEN also contained typical
mouse chromosomes with 89 of 100 metaphases having
36-40 chromosomes and 11 metaphases with 79 chromo-
somes. Two marker chromosomes were noted in P388/MEN.
The first marker chromosome (M1) was the same as noted
for P388/0, the second marker was a # I chromosome with
a variable staining HSR segment attached to the p arm and
occurred in 50% of the karyotypes examined. P388/MEN
had three double minutes in the 30 metaphases examined,
P388/0 had a minute chromosome in 2 of 30 metaphases
examined. These results show no significant difference
between the sensitive and resistant cell lines in modal number
or minute chromosomes, with very few double minutes in
P388/MEN.
P388/MEN and P388/ADR demonstrate different cross resist-
ance patterns Growth inhibition assay (ID_0) showed P388/
MEN was 40-fold more resistant to menogaril than the
sensitive P388/0 cells and was cross-resistant (i.e., 60-fold
more resistant) to adriamycin. P388/MEN was not cross-
resistant to Velban and actinomycin D, and was collaterally
sensitive to cisplatin (Table I) compared to P388/0. In
contrast, P388/ADR was cross-resistant to all these com-
ponents.
Verapamil does not reverse menogaril resistance in P388/MEN
cells Verapamil has been shown to reverse adriamycin re-
sistance by decreasing drug efflux, presumably by verapamil
binding to the efflux pump, gp 170 (Riordan et al., 1985).
Therefore, we tested the ability of verapamil to reverse the
growth inhibition by menogaril of P388/0, P388/MEN and
Table I Cross-resistance pattern for P388/MEN and P388/ADR
Relative Resistance Indexb
P388/MEN P388/ADR
Drug ID50, IDJD ID"0 IDw
Menogaril 43 20 30 19
Adriamycin 60 53 896 1300
Cisplatin 0.32 1.0 9.5 11
Actinomycin D 0.87 1.2 75 446
Velban 0.72 1.1 137 43
aI) and ID---I values were determined after 72-hour continuous
exposure to drug. Values are averages of 2-3 experiments and
greatest variation was less than 10%. bRelative Resistance
Index = ID50 Resistant . ID%o Sensitive or ID,0 resistant + ID90
sensitive. Thus, an index of 1.0 indicates that the parent (sensitive)
and resistant cell lines are equally sensitive to the test drug. An index
of < 1.0 indicates collateral sensitivity, i.e., resistant cell lines are
more sensitive than the parent, and an index of > 1.0 indicates
resistance or cross-resistance to the test drug.MENOGARIL-RESISTANT P388 CELLS 381
P388/Adr cells (Figure 2a). Figure 2b shows the response of
these cells to adriamycin, with or without verapamil. Figure
2a shows that verapamil did not affect growth inhibition by
menogaril of P388/MEN (compare O,) or P388/0 (com-
pare 0,0) which suggests that menogaril resistance was not
mediated through increased drug efflux by gp 170. But, in
agreement with the observation of Harker & Sikic (1985),
verapamil increased growth inhibition by adriamycin of
P388/Adr (Figure 2b compare A,A). Thus, 0.5ttg ml-'
adriamycin inhibited growth of P388/Adr only 10% as com-
pared to 90% inhibition in the presence of verapamil. This
confirms that adriamycin resistance in P388/Adr was
mediated through increased drug efflux by gp 170. Figure 2b
shows that, at the 50% inhibition level, there was a 2-fold
increase in sensitivity of both P388/MEN (compare 0,E)
and P388/0 (compare 0,0) to adriamycin in the presence of
verapamil compared to its absence. P388/Adr was 2-fold
more sensitive to menogaril in the presence of verapamil
(Figure 2a compare A,A) which suggests that the P-
glycoprotein present in P388/Adr may be involved in efflux
of menogaril.
Uptake and efflux of menogaril is similar in P388/0 and
P388/MEN cells Cellular uptake was measured during 2 h
incubation with drug, following which the cells were washed
and resuspended in growth medium to measure efflux during
the next 3 h. Uptake of menogaril into P388/0 and P388/
MEN cells was rapid with most of the drug taken up within
30 min (Figure 3). During uptake at 0.3 Lg ml' menogaril,
P388/0 had an intracellular concentration 1-2 times that of
P388/MEN. Efflux was equally rapid in both cell lines with
most of the drug effluxed by 30 min. At 1.0iLgml-', P388/0
cells initially had more (- 2-fold) menogaril than P388/MEN
but both cell lines had similar intracellular menogaril content
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Figure 2 a, Growth inhibition of P388 cells exposed to
menogaril, alone or menogaril plus 10 JM verapamil.
O O, P388/0 + menogaril; 0 ------ *, P388/0 +
menogaril + verapamil; 0 O, P388/MEN + menogaril;
, P388/MEN + -menogaril + verapamil;
V V, P388/Adr + menogaril; V V, P388/Adr +
menogaril + verapamil. b, Growth inhibition of P388 cells
exposed to Adriamycin alone or Adriamycin with 10 JM
verapamil. 0 O, P388/0 + Adr; * *, P388/0 +
Adr + verapamil; 0 0, P388/MEN + Adr;E *,
P388/MEN + Adr + verapamil; V V, P388/Adr + Adr;
V V, P388/Adr + Adr + verapamil.
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Figure 3 Uptake and efflux of menogaril in P388/0 cells (open
symbols) and P388/MEN cells (closed symbols). 0.3jig ml
menogaril (O,), 1.0 igml menogaril (A,A) and 8.0tgml
menogaril (*). Values are shown for uptake (0-120min) and
efflux (150-300min). Cells were exposed to menogaril for 2h
during which intracellular uptake was measured. Then the cells
were washed with medium and resuspended in drug-free medium
and incubated for 3 h. Intracellular drug content was measured
during this period to determine drug efflux.
by 2 h. However, efflux was much more rapid in P388/MEN
cells compared to P388/0 cells so that 3 h after drug
removal, P388/0 cells had 8 times more menogaril than
P388/MEN. At 8Itg ml-' drug efflux was very slow in P388/
MEN (see discussion).
DNA and RNA hybridisation analyses demonstrates P388/
MEN does not significantly amplify or overexpress a mdr
gene Multidrug resistance has been correlated with the
amplification of the mdr gene(s) in Chinese hamster ovary
(CHO) and human KB cells. We, therefore, investigated the
amplification of a mdr gene in P388/0, P388/MEN, and
multidrug resistant P388/Adr (Figure 4). DNA and RNA
isolated from these cell lines were hybridised to 32P-labelled
pDR 1.6, a pUCl9 plasmid carrying a conserved region of a
hamster mdr gene. P388 DNA fragments of 5 and 19 kbp
hybridised with this probe and no amplification of these
DNAs occurred in P388/MEN or P388/ADR compared to
the P388/0 DNA. The control DNAs from the multidrug
resistant CHrC5 cell line showed greater than 30-fold
amplification of the 19 kbp DNA fragment compared to the
drug sensitive AuxBl cell. The expression of mdr mRNA was
analysed to investigate whether P388/MEN cells were overex-
pressing the mdr locus without amplification of the gene
itself. Northern analysis with pDR 1.6 indicated that the
MDR transcript is barely detectable in P388/0 and P388/
MEN mRNAs (Figure 4). In contrast, RNA from CHrC5
cells had greater than 20 times more mdr mRNA compared
to AuxBl mRNA. Interestingly, P388/ADR did show about
a 20-fold increase in expression of MDR transcript. Several
other menogaril-resistant P388 clones were examined and
these clones gave similar results to those of the P388/MEN
cells.
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Figure 4 DNA and RNA hybridisation analysis: a, Lanes I to 5:
isolated cellular DNA (1 0 fig) digested with bamHlI and run on
an 0.8% agarose gel was hybridised with 32P-labelled pDR 1.6.
Lane I CHO-Auxl (sensitive), Lane 2 CHrC5 (colchicine-
resistant CHO), Lane 3 -P388/0, Lane 4 P388/MEN, Lane 5
P388/ADR. b, Lanes 6 to 10: Total cellular RNA (10 psg glycox-
ylated) was separated on a 1.5% agarose gel and hybridised with
32P labelled pDR 1.6 fragment. Lane 6- AuxBI, Lane 7-
CHrC5, Lane 8- P388/0, Lane 9- P388/ADR, Lane 10-
P388/MEN.
Cellular glutathione (GSH) does not modulate menogaril re-
sistance Increased GSH levels have been associated with-
resistance to several alkylating agents and to adriamycin
(Green et al., 1984; Hamilton et al., 1985). Also, lowering
GSH levels by pretreating cells with buthionine sulfoximine
potentiated adriamycin cytotoxicity in human ovarian and
breast tumour cell lines (Hamilton et a!., 1985; Dusre et al.,
1989). Therefore, we tested whether GSH was involved in
menogaril resistance. For this purpose, we compared GSH
levels in sensitive and resistant cell lines and also determined
whether buthionine sulfoximine treatment can potentiate
menogaril toxicity. Table shows that the GSH content of
P388/MEN cells was similar to that of the sensitive (P388/0)
cells whereas P388/ADR contained twice as much GSH as
P388/0 cells. Pretreatment of P388/ADR cells with a non-
toxic dose (100p~m for 24 h) of buthionine sulfoximine
lowered cellular GSH content to that of P388/0. Pretreat-
ment for 24 h with a non-cytoxic (1 00 gtm) dose of buthionine
sulfoximine did not potentiate menogaril toxicity to P388/
MEN or P388/0 cells. However, after buthionine sulfoximine
pretreatment, P388/ADR cells (adriamycin ID50
=
1.18 fig ml-') were slightly more sensitive to adriamycin than
untreated P388/ADR cells (adriamycin ID50 =a1.71 fig ml-').
In vivo studies show P388iMEN cells are tumorigenic and
refractory to the optimal dose of menogaril P388/MEN and
P388/0 cells were serially passaged in vitro for more than one
year during which P388/MEN was in the continuous
presence of menogaril. When P388/0 and P38/MEN in vitro
cultures were reintroduced into mice, the median day of
death (MDD
= 17-19 days) was greater than that of P388 in
vivo stock cultures (MDD
= 10 days) which had been pas-
saged in vivo (Table III). When challenged with menogaril,
the P388/MEN cell line was refractory to the optimal dose
while the P388/0 cells remained sensitive. With each repeated
passage in vivo, the MDD in the untreated control decreased
until it stabilised at 9-10 days. By the 6th passage, 30%
increase in lifespan was seen in the menogaril treated P388/
MEN tumour-bearing animals compared to 200-300% in-
crease in life span for P388/0 tumour-bearing animals. Even
after 9 in vivo passages the P388/MEN line remained resist-
ant to therapeutic doses of menogaril compared to P388/0.
Table II Cellular glutathione
GSH
Cell line nmoleIO6cells nmole mg Iprotein
P388/0 4.9 + 0.5 (100%)' 24.7 (100%)
P388/MEN 3.9 0.9 (79.6%) 20 (81%)
P388/ADR 10.3 ±0.4 (210.2%) 48.5 (196.3%)
P388/ADR + BSOb 4.5± 0.3 (91.8%) 19.4 (78.5%)
'The values within parentheses compare the GSH content of the
cell lines to that of P388/0. bP388/ADR cells were treated with
100JLM buthionine sulfoximine for 24h.
Table III In vivo response of P388/0 and P388/MEN to optimal
dose of menogaril
P388/10 P388/MEN'
Passage MDDb MDD MDD MDD
Number untreated 25 mgkg-' untreated 25 mgkg-'
1 17.5 19
2 15 32 17.5 18
3 14 13 14
4 11.5 22 13 15
6 10 42 (2/8) 10 13.5
9 10 32 (4/32) 10 13
'P388/0 and P388/MEN cells (106) were injected i.p. on day 0.
Menogaril (25fig kg-') was injected i.p. on days 1, 5 and 9. bMedian
day of death (MDD) of the untreated control P388/0 or P388/MEN
decreased as passage number increased until it stabilised at 9-10
days. P388/MEN remained resistant to menogaril for at least 4
months. Cures are noted in parentheses.
Discussion
Resistance of P398 cells to menogaril was achieved by con-
tinuous exposure of the suspension culture to increasing drug
concentrations. We also used an alternate method of selec-
ting drug-resistant cells by cloning viable cells in soft agar at
each step of increasing drug level. This method worked well
but did not generate a resistant population any faster than
the present method. It should be noted that potent mutagens
were not used to generate resistant variants. As the culture
adapted to continuous drug exposure, the time between step-
wise increase in drug dose decreased, i.e., resistance
developed faster. Rapid increase in resistance at the later
stages was also reported by Beran & Anderson (1987) during
development of resistance to m-AMSA.
Lower drug uptake and/or more efficient efflux often
account for the lower drug sensitivity of the resistant cell line
(Harker & Sikic, 1985). However, it is difficult to decide what
dose of drug to use in uptake experiments since the sensitive
and resistant cell lines are so different in their drug sen-
sitivity. The dose should be high enough to cause signifi-
cant cytoxicity without damaging the efflux mechanism. At
0.3 sg ml1' menogaril, which is the LD90 for P388/0 and
nontoxic to P388/MEN, the difference in uptake and efflux
between the 2 cell lines was small. At 1 ggml m1', which is
highly toxic (>LDg9) to P388/0, efflux was very slow, prob-
ably because the efflux mechanism was damaged. However,
efflux was normal at the I fig ml' dose in P388/MEN,
although it was inhibited at 81g ml-'. Based on the results
at 0.3jig ml-' we concluded that uptake and efflux differ-
ences are not likely to explain the difference in sensitivity
between P388/0 and P388/MEN.
Gene amplification in drug resistant cell lines has been
correlated with the appearance of double minutes and HSR
in the karyotypes (Robertson et al., 1984). P388/0 and P388/
MEN had very similar karyotypes with the resistant line
having an extra marker chromosome which did have a
somewhat variable HSR. It is unlikely that the HSR or small
number of double minutes can account for menogaril resis-
tance. This is based on our observation that P388/MEN cells
fused with S49 mouse lymphoma cells retain menogaril resist-
ance but do not have the HSR (Badiner et al., 1986b).
P388/MEN cells did not meet the established criteria for
the multidrug resistant phenotype as seen for otherMENOGARIL-RESISTANT P388 CELLS 383
anthracycline resistant cells (Robertson et al., 1984; Kartner
et al., 1983). There was not enough difference in uptake or
efflux of menogaril to explain the large increase in resistance.
Resistance of P388/MEN to menogaril was not reversed by
verapmil. P388/MEN cells have a limited pattern of cross-
resistance in that they are cross-resistant only to adriamycin
but not cross-resistant to cisplatin, Velban or actinomycin D.
We used the hamster pDR 1.6 DNA probe to show that
there was no significant amplification of the mdr gene, nor
overexpression of this gene as mRNA in P388/MEN. A
family of genes has been associated with multidrug resistance
and expression of the MDR phenotype. We have investigated
one such gene. Other MDR associated genes may, or may
not, be important in menogaril resistance in P388 cells.
Several examples of drug resistance to anthracyclines or
other natural products (e.g., etoposides, VM-26 or VP-16)
that do not involve overexpression of P-glycoprotein have
been published. Danks et al. (1987) reported the 'atypical'
multidrug resistance characteristics of a teniposide (VM-26)
resistant human leukaemic (CEM) cell line. They showed
that drug resistance was not due to P-glycoprotein-mediated
decreased intracellular drug concentration but was probably
due to altered interaction between drug and cellular target.
Slovak et al. (1988) also reported different mechanisms of
Adr resistance in 2 human cell lines. Adr resistance in LoVo
cells correlated with P-glycoprotein increase whereas a non-
P-glycoprotein mediated mechanism operated in HT1080
cells. Resistance to Adr can be multifactorial and result from
decreased drug uptake, decreased formation of DNA strand
breaks and early onset of repair, increased glutathione trans-
ferase activity and elevated P-glycoprotein activity (Deffie et
al., 1988). Reduced topoisomerase activity has also been
reported to correlate with Adr resistance (Deffie et al., 1989).
It is possible that some of these mechanisms may account for
menogaril resistance.
Our results clearly show that GSH is not likely to be
involved in menogaril resistance in P388/MEN cells. GSH
content of P388/MEN cells was not increased over that of
the sensitive cell line and the cytotoxicity of menogaril was
not potentiated when GSH concentration was lowered by
pretreatment with buthionine sulfoximine. Our results suggest
that GSH may be involved in adriamycin resistance of P388/
ADR cells. P388/ADR cells contained twice as much GSH as
the sensitive cell line and lowering GSH content potentiated
adriamycin toxicity about 1.5-fold. The GSH content of our
P388/0 cells was similar to that reported by Ramu et al.
(1984). They also observed a 1.5-fold increase in GSH and
GSH-peroxidase content of P388/ADR cells over that of the
sensitive cells. However, they did not see any potentiation of
drug cytotoxicity when P388/ADR cells were treated with
adriamycin after glutathione depletion by 1-chloro-2,4-
dinitrobenzene. Potentiation of adriamycin cytotoxicity by
GSH depletion has been reported for human tumour cell
lines. Hamilton et al. (1985) reported that in both sensitive
and adriamycin-resistant ovarian carcinoma cell lines GSH
depletion potentiated adriamycin cytotoxicity. Dusre et al.
(1989) also reported potentiation of adriamycin cytoxicity in
multidrug resistant human breast tumour cells. The
phenotype of the resistant cell line depends on the cell line
and the drug to which it is resistant. The same cell line, P388,
made resistant to two different anthracyclines (menogaril or
adriamycin) displayed different phenotypes. P388/MEN had
a non-multidrug resistant phenotype while P388/ADR fit the
established criteria for the MDR phenotype. When the same
drug, menogaril, was used to develop two different resistant
cell lines, P388/MEN and (Chinese hamster) V79/MEN, the
phenotypes were again different. P388/MEN had a non-
multidrug resistant phenotype whereas V79/MEN cells had
the MDR phenotype (Badiner et al., 1987a).
In the light of the difference between P388/MEN and
V79/MEN, the clonal heterogeneity of P388/MEN, as ex-
pressed by differences in clonogenicity and differences in the
level of resistance to menogaril become interesting. The
clonal heterogeneity may indicate the existence in P388/MEN
of a variety of resistance mechanisms, some of which may be
of the MDR type. Such information may be relevant to
clinical evaluation of menogaril. The P388/MEN tumour was
refractory to therapeutic doses of menogaril and this resis-
tance was stable for at least 12 weeks in vivo. Further studies
on the in vivo cross-resistance pattern of P388/MEN show
interesting differences from that seen in vitro (Badiner et al.,
1987c). These observations may be important in the selection
of appropriate cell lines for the study of drug resistance.
We thank P. Gros for the pDR 1.6 probe (McGill University, Mont-
real, Quebec, Canada); R. Ulrich for the electron micrographs, and
J. Brewer and W. Adams for HPLC analysis (all of The Upjohn
Company, Kalamazoo, MI 49001). We also thank C.A. Kiewiet for
secretarial assistance with many copies of this manuscript.
References
BADINER, G.J. & BHUYAN, B.K. (1986a). The evolution and charac-
terization of P388 cells resistant to menogaril. Proc. Am. Assoc.
Cancer Res., 27, 265.
BADINER, G.J., GROPPI, V.E. & BHUYAN, B.K. (1986b). Resistance to
menogaril is a codominant phenotype in mouse lymphoma cells.
J. Cell. Biol., 10, 28a.
BADINER, G.J., BICHAY, T.J. & BHUYAN, B.K. (1987a). Menogaril
resistance results in amplification of mdr gene in Chinese hamster
V79 cells but not in mouse leukemia P388 cells. Proc. Am. Assoc.
Cancer Res., 28, 281.
BADINER, G.J., HAMILTON, R.D., LI, L.H. & BHUYAN, B.K. (1987b)
Drug sensitivity of ten human tumor cell lines compared to
mouse leukemia (L1210) cells. Inv. New Drugs, 5, 219.
BADINER, GJ., WILSON, D.K., LI, L.H. & BHUYAN, B.K. (1987c).
Comparison of in vivo and in vitro cross-resistance patterns for
P388 sensitive and P388 menogaril resistant cells. Proc. Am.
Assoc. Cancer Res., 28, 299.
BECH-HANSEN, N.T., TILL, J.E. & LING, V. (1975). Pleiotropic
phenotype of Colchicine-resistant CHO cells: cross-resistance and
collateral sensitivity. J. Cell. Physiol., 88, 23.
BERAN, M. & ANDERSON, B.S. (1987). Development and charac-
terization of a human myelogenous leukemia cell line resistant to
4'-(9-acridinylamino)-3-methanesulfon-m-anisidide. Cancer Res.,
47, 1897.
BHUYAN, B.K., BLOWERS, C.L. & SHUGARS, K.D. (1980). Lethality
of nogalamycin, nogalamycin analogs, and Adriamycin to cells in
different cell cycle phases. Cancer Res., 40, 3437.
CHIRGWIN, J.M., PRZYBYLA, A.A., MACDONALD, R.J. & RUTTER,
W.J. (1989). Isolation of biologically active ribonucleic acid from
sources enriched in ribonuclease. Biochem., 18, 5294.
DANKS, M.K., YALOWICH, J.C. & BECK, W.T. (1987). Atypical mult-
iple drug resistance in a human leukemic cell line selected for
resistance to teniposide (VM-26). Cancer Res., 47, 1297.
DEFFIE, A.M., ALAM, T., SENEVIRATNE, C. & 5 others (1988).
Multifactorial resistance to Adriamycin: relationship to DNA
repair, glutathione transferase activity, drug efflux, and P-glyco-
protein in cloned cell lines of Adriamycin-sensitive and -resistant
P388 leukemia. Cancer Res., 48, 3595.
DEFFIE, A.M., BATRA, J.K. & GOLDENBERG, G.J. (1989). Direct
correlation between DNA topoisomerase II activity and cytotoxi-
city in Adriamycin-sensitive and resistant P388 leukemia cell
lines. Cancer Res., 49, 58.
DUSRE, L., MIMNAUGH, E.G., MYERS, C.E. & SINHA, B.K. (1989).
Potentiation of doxorubicin cytotoxicity by buthionine sulfoxi-
mine in multidrug-resistant human breast tumor cells. Cancer
Res., 49, 511.
FEINBERG, A.P. & VOGELSTEIN, B. (1984). A technique for
radiolabelling DNA restriction endonuclease fragments to high
specific activity. Anal. Biochem., 137, 266.
GREEN, J.A., VISTICA, D.T., YOUNG, R.C., HAMILTON, T.C.,
ROGAN, A.M. & OZOLS, R.F. (1984). Potentiation of melphalan
cytotoxicity in human ovarian cancer cell lines by glutathione
depletion. Cancer Res., 44, 5427.384 G.J. BADINER et al.
GROS, P., GROOP, J., RONINSON, I., VARSHAVSKY, A. & HOUSMAN,
D.E. (1986). Isolation and characterization of DNA sequences in
multidrug-resistant hamster cells. Proc. Natl Acad. Sci., 83, 337.
HAMILTON, T.C., WINKER, M.A., LOUIE, K.G. & 7 others (1985).
Augmentation of Adriamycin, melphalan, and cisplatin cytotox-
icity in drug-resistant and -sensitive human ovarian carcinoma
cell lines by buthionine sulfoximine mediated glutathione de-
pletion. Biochem. Pharmacol., 34, 2583.
HARKER, W.G. & SIKIC, B.I. (1985). Multidrug (pleiotropic) resist-
ance in Doxorubicin-selected variants of the human sarcoma cell
line MES-SA. Cancer Res., 45, 4091.
JOHNSON, R.K., CHITNIS, M.P., EMBREY, W.M. & GREGORY, E.B.
(1978). In vivo characteristics of resistance and cross-resistance of
an Adriamycin-resistant subline of P388 leukemia. Cancer Treat.
Rep., 62, 1535.
KARTNER, N., SHALES, M., RIORDAN, J.R. & LING, V. (1983).
Daunorubicin-resistant Chinese hamster ovary cells expressing
miltidrug resistance and a cell-surface P-glycoprotein. Cancer
Res., 43, 4413.
KAYE, S. & MERRY, S. (1985). Tumor cell resistance to
anthracyclines-a review. Cancer Chemother. Pharmacol., 14, 96.
KLOHS, W.C., STEINKAMPF, R.W., HAVLICK, M.J. & JACKSON, R.D.
(1986). Resistance to anthrapyrazoles and anthracyclines in
multidrug-resistant P388 murine leukemia cells: reversal by cal-
cium blockers and calmodulin antagonist. Cancer Res., 46, 4352.
LI, L.H., KUENTZEL, S.L., MURCH, L.L., PSCHIGODA, L.J. &
KRUEGER, W.C. (1979). Comparative biological and biochemical
effects of nogalamycin and its analogs on L1210 leukemia.
Cancer Res., 39, 4816.
LING, V. & THOMPSON, L.H. (1974). Reduced permeability in CHO
cells as a mechanism of resistance to colchicine. J. Cell. Physiol.,
83, 103.
MANIATIS, T., FRITSCH, E.F. & SAMBROOK, J. (1982). Purification
of nucleic acids. In: Molecular cloning - a laboratory manual,
p. 458. Cold Spring Harbor Laboratory.
MCGOVREN, J.P., NEIL, G.L., DENLINGER, R.H., HALL, T.L.,
CRAMPTON, S.L. & SWENBERG, J.A. (1979). Chronic cardiotoxi-
city studies in rabbits with 7-con-O-methylnogarol, a new
anthracycline antitumor agent. Cancer Res., 39, 39, 4849.
MCGOVREN, J.P. (1980). Activity of the anthracycline agent, 7-con-
0-methylnogarol (7-OMEN) administered orally to mice bearing
P388 or L1210 leukemia. Cancer Treat. Rep., 64, 727.
McGOVREN, J.P., HAMILTON, R.D., ADAMS, W.J. & PRATT, E.A.
(1984). Quantitation of anthracycline antitumor agent menogarol
in plasma using liquid chromatography with fluorescence detec-
tion. Anal. Chem., 56, 1587.
MOY, B.C., TARPLEY, W.G., GROPPI, V.E., BADINER, G.J. &
BHUYAN, B.K. (1986). Molecular characterization of P388 mouse
leukemia cells resistant to the anthracycline antibiotic, menogaril.
Proc. Am. Assoc. Cancer Res., 27, 300.
NAKASHIMA, K., NISHIDA, K., NAKATSUJI, S. & AKIYAMA, S.
(1986). Development and application of organic reagents for
analysis. VIII. Determination of biological thiols with a new
fluorogenic thiol-selective reagent. N-{p-[2-(6-dimethylamino)-
benzofuranyl]phenylpmaleimide. Chem. Pharm. Bull., 34, 1678.
NEIL, G.L., KUENTZEL, S.L. & McGOVREN, J.P. (1979). Treatment of
mouse tumors with 7-con-0-methylnogarol and other analogs of
the anthracycline antibiotic, nogalamycin. Cancer Treat. Rep., 63,
1971.
OTTENBREIT, M.J., HALTON, D.M. & PETERSON, W.D. Jr. (1983).
Rapid isoenzyme analysis of cell cultures by agarose electro-
phoresis. II. Intraspecies identification of human cell lines. J.
Tissue Culture Methods, 8, 125.
PETERSON, W.D. Jr., SIMPSON, W.F. & HUKKU, B. (1979). Cell cul-
ture characterization, monitoring for cell identification. Methods
in Enzymology. Vol. 158, p. 164. Academic Press: New York.
RAMU, A., COHEN, L. & GLAUBIGER, D. (1984). Oxygen radical
detoxification enzymes in doxorubicin-sensitive and -resistant
P388 murine leukemia cells. Cancer Res., 44, 1976.
RIORDAN, J.R., DEUCHOVE, K., KARTNER, N., ALON, N., TRENT, J.
& LING, V. (1985). Amplification of P-glycoprotein genes in
multidrug-resistant mammalian cell lines. Nature, 316, 817.
ROBERTSON, S.M., LING, V. & STANNERS, C.P. (1984). Co-
amplification of double minute chromosomes, multiple drug re-
sistance, and cell surface P-glycoprotein in DNA-mediated trans-
formants of mouse cells. Mol. Cell. Biol., Vol. 4, p. 500.
SCHABEL, F.M. Jr, SKIPPER, H.E., TRADER, M.W., LASTER, W.R. Jr,
GRISWOLD, D.P. Jr & CORBETT, T.H. (1983). Establishment of
cross-resistance profiles for new agents. Cancer Treat. Rep., 67,
905.
SLOVAK, M.L., HOELTGE, G.A., DALTON, W.S. & TRENT, J.M.
(1988). Pharmacological and biological evidence for differing
mechanisms of doxorubicin resistance in two human tumor cell
lines. Cancer Res., 48, 2793.
STERNBERG, C., MAGILL, G., CHENG, E. & HOLLANDER, P. (1986).
Phase II trial of menogaril in patients with adenocarcinoma of
the pancreas. Proc. Am. Assoc. Cancer Res., 27, 240.
WEISS, G.R., VON HOFF, D.D., McGOVREN, J.P., NEIL, G.L. &
PAQUE, R.E. (1983). Antitumor Activity of 7-Con-O-
methylnogarol (7-OMEN) in the human tumor clonogenic assay.
Proc. Am. Assoc. Cancer Res., 24, 309.